Guest Edited by Ryan C. Fields and Anna Golebiewska
Guest Edited by: Orazio Fortunato, Irina Matei and Chunlin Ou
This article studies the effects of urinary EVs from PC patients and healthy males on the transcriptional landscape of prostate CAFs and normal foreskin fibroblasts.
This study aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS).
This study shows the potential use of superparamagnetic iron oxide (SPIO) and pre-operative MRI in melanoma patients to identify SLNs.
Click here to view which Articles have been shared most in the last month!
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Learn more about study protocols at BMC Cancer here
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
Pancreatic cancer accounts for about 3% of all cancers in the US and is projected to become the second leading cause of cancer-related death by 2030.
On occasion of the Pancreatic Cancer Awareness Month we hope you will enjoy reading one of the newest study protocol published in BMC Cancer in 2022 aiming to enhance chemosensitivity and drug distribution in pancreatic cancer through CAF conversion in the stroma.
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma
Interested in joining the editorial board of BMC Cancer?
More information and how to apply can be found here. We are looking forward to hearing from you.
Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades.
21 November 2022
37 days to first decision for all manuscripts (Median)
65 days to first decision for reviewed manuscripts only (Median)
6,897,358 Downloads (2021)
4,517 Altmetric mentions (2021)
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication